NCT03907163 is a NA clinical trial of Dronabinol in Retinal Blood Flow, sponsored by Medical University of Vienna.

Who is sponsoring NCT03907163?

NCT03907163 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT03907163?

Interventions in NCT03907163: Dronabinol, Placebo.

What condition does NCT03907163 study?

NCT03907163 studies Retinal Blood Flow.

Is NCT03907163 still recruiting?

NCT03907163 is currently completed. Last updated 10 April 2019.

Last reviewed 2019-04-10 · How we verify

NCT03907163

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Tetrahydrocannabinol on Ocular Hemodynamics in Healthy Subjects

Completed NA Last updated 10 April 2019

What this trial tests

NA trial testing Dronabinol in Retinal Blood Flow in 24 participants. Completed in 27 November 2018.

Timeline

2 July 2018

Primary endpoint
27 November 2018

27 November 2018

Quick facts

Lead sponsor	Medical University of Vienna
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	diagnostic
Enrollment	24
Start date	2 July 2018
Primary completion	27 November 2018
Estimated completion	27 November 2018
Sites	1 location across Austria

Drugs / interventions tested

Dronabinol (DRONABINOL) — full drug profile →
Placebo

Conditions studied

Retinal Blood Flow — all drugs for Retinal Blood Flow →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 35, any sex, with Retinal Blood Flow. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Glaucoma is among the leading causes for irreversible blindness worldwide. While lowering intraocular pressure (IOP) remains the mainstay of therapy, there are still some patients who progress despite wellcontrolled IOP. There is evidence from several studies that ocular blood flow and its regulation is impaired in patients with glaucoma. Tetrahydrocannabinol (THC) has been used in the treatment for glaucoma in some countries for several years due to its IOP lowering effect. In addition, there is also evidence that THC features neuroprotective effects and improves ocular hemodynamics. Dronabinol is a synthetic THC that is legally available in several European countries. It has the advantage that exact dosing of THC is possible in contrast to previously applied administration forms such as smoking. Due to its legal status in the past, data about the effect of THC on ocular blood flow and its regulation are sparse. This holds true for basic research in healthy subjects as well as in patients with glaucoma.The aim of the present study therefore is to investigate whether single administration of THC alters optic nerve head (ONH) blood flow in healthy subjects. In addition, other parameters for ocular blood flow will be measured, in particular retinal blood flow, retinal oxygen saturation and retinal neurovascular coupling. The study will be conducted in a randomized, double-masked, placebocontrolled, two-way cross-over design. Subjects will receive 5mg dronabinol on one study day. This dose is the recommended starting dose for some indications in clinical practice. Other studies investigating retinal hemodynamics or IOP after administration of THC also have used similar or slightly higher doses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dronabinol

Trials testing the same drug.

NCT07225777 — Sex Differences in Neurobehavioral Response to THC · Phase 2 · not yet recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
NCT06477952 — DRonabinol Treatment of OSA · Phase 1, PHASE2 · recruiting
NCT05865470 — Age-dependent Effects of Smoked and Oral Delta-9-THC · Phase 1 · recruiting
NCT05519111 — Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain · Phase 2 · recruiting

Other recruiting trials for Retinal Blood Flow

Currently open trials in the same condition.

NCT03552562 — Measurement of Total Retinal Blood Flow and Oxygen Extraction in Patients With Diabetes and Healthy Subjects · NA · recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03907163 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 10 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03907163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing